Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.39 |
| ▸ | PRKCG | P05129 | 4/20 | 0.39 |
| ▸ | PRKCB | P05771 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | PRKCA | P17252 | 4/20 | 0.39 |
| ▸ | PRKCH | P24723 | 4/20 | 0.39 |
| ▸ | PRKCI | P41743 | 4/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.39 |
| ▸ | PRKACA | P17612 | 3/20 | 0.39 |
| ▸ | PRKACG | P22612 | 3/20 | 0.39 |
| ▸ | PRKACB | P22694 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343775 | 0.92 | HTR6 (0.42) | CYP17A1KDM4EALDH1A1 | |
| SCHEMBL4341437 | 0.87 | LMNA (0.47) | CYP17A1MEN1KMT2AALOX15TSHR | |
| SCHEMBL4329436 | 0.84 | TSHR (0.41) | CYP17A1MEN1KMT2ATP53TSHR | |
| SCHEMBL4338245 | 0.81 | BRD4 (0.41) | PRKCAKDM4EHSD17B10SMN1; SMN2MAPK1 | |
| SCHEMBL13666638 | 0.81 | TSHR (0.41) | CYP17A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL4335494 | 0.80 | PDE4A (0.39) | AAK1MAPK1KIT | |
| SCHEMBL4333431 | 0.80 | NOD2 (0.47) | CYP2C19AAK1CDK8 | |
| SCHEMBL4337652 | 0.79 | MEN1 (0.48) | KDM4EMEN1KMT2AHSD17B10TSHR | |
| SCHEMBL4330189 | 0.78 | PDE4D (0.50) | MEN1KMT2AMAPK1KIT | |
| SCHEMBL4334958 | 0.78 | BRD4 (0.40) | PRKCAMEN1KMT2AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605168-B2 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605168-B2 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605168-B2 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1786813-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | CYP17A1 1328/4885ROCK2 379/4885P2RX7 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.